Hangzhou Diagens Biotechnology Co., Ltd. (DIAGENS-B) aksje

Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Software and Medical Devices, Technology Licensing, Analysis and Consulting Services, and Others segments. The company's products portfolio include AI AutoVision, a chromosome karyotype assisted diagnosis and analysis system that provides intelligent karyotyping analysis with applications across genetics and hematologic oncology; MetaSight automatic cell microscopic image scanning system, which enables automated scanning, positioning, image acquisition, and output of chromosome or cell samples for a range of cytogenetics applications, including genetics health, radiation health, and hemato-oncology; and KayoFlow automatic cell harvester for pre-analytical processing of various sample types, including peripheral blood, amniotic fluid, and bone marrow. It also offers KayoFlow integrated slide preparation and staining system for pre-analytical slide preparation and staining of chromosome samples; KayoFlow workflow integration systems; and laboratory reagents and consumables. In addition, the company provides integrated storage, computation, training, and inference localized solutions; and iMed MaaS medical imaging AI platform, a cloud-based service platform. Hangzhou Diagens Biotechnology Co., Ltd. was founded in 2016 and is headquartered in Hangzhou, China.